Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

NCT00920816 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

492

Enrollment

INDUSTRY

Sponsor class

Conditions

Kidney Neoplasms

Interventions

DRUG: Axitinib (AG-013736)
DRUG: Sorafenib

Sponsor

Pfizer